<DOC>
	<DOC>NCT02955459</DOC>
	<brief_summary>This is a 2-part, first-in-human dose-ranging study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of VNRX-5133 administered via intravenous (IV) infusion in healthy subjects. In part 1, subjects will receive a single dose of VNRX-5133; in part 2 subjects will receive VNRX-5133 for 7 days.</brief_summary>
	<brief_title>VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Healthy adults Males or nonpregnant, nonlactating females Body Mass Index (BMI) between 18.5 32.0, inclusive. Suitable veins for cannulation Employee of site or the sponsor Any disease that poses an unacceptable risk to participants Abnormal ECG Abnormal labs Abnormal vital signs Current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, autoimmune, hematologic, neoplastic, or neurological disorder Positive serology for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) type 1 Current smokers or history of smoking within 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Healthy volunteers</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>